Biotech

Spilled martini on green background
Biotech

Vedanta's live bacteria cocktail fails phase 2 colitis trial

Vedanta is reorienting resources toward lead candidate VE303, which is chasing the tail of Seres’ Vowst in treating recurrent C. diff infections.
Darren Incorvaia Aug 13, 2025 1:48pm
dollar sign with colored arrows in a maze

Hatteras handles $200M across 2 funds for life science startups

Aug 13, 2025 10:28am
Carl Sailer on AI market trends and strategic planning in biotech

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm
workers

Fierce Biotech Layoff Tracker 2025: Abata, Fate & more

Aug 13, 2025 10:05am
Guidehouses Karla Anderson shares top tips for successful biotech commercialization

Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization

Oct 28, 2024 8:00am
obesity overweight weight loss weigh

Response’s ex-Sanofi asset hits goal in post-GLP-1 patients

Aug 13, 2025 9:14am